Navigation Links
Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- Proteolix, Inc. announced today that data from two Phase 1 clinical studies using intravenous carfilzomib (PR-171) are to be presented at the 2007 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, December 8-10, 2007. Carfilzomib is a potent and selective proteasome inhibitor currently being investigated for the treatment of multiple myeloma, lymphoma and solid tumors.

Robert Z. Orlowski, M.D., Ph.D., of the University of Texas, M.D. Anderson Cancer Center, and Melissa Alsina, M.D., of the H. Lee Moffitt Cancer Center and Research Institute, will be presenting data from two Phase 1 clinical studies in relapsed and refractory hematologic malignancies on Monday, December 10 beginning at 11:00 am and 11:30 am EST, respectively, in a session entitled "Novel Therapies in Relapsed Myeloma." Additional information about the 2007 ASH Annual Meeting can be found on the ASH website at http://www.hematology.org/meetings/2007.

"We are very pleased that carfilzomib can be dosed on a consecutive-day schedule in humans, as was predicted by animal studies," said Susan M. Molineaux, Ph.D., President and CEO of Proteolix. "These early results showing single-agent activity in myeloma indicate the potential of this product candidate to help persons afflicted with the disease. We look forward to data throughout 2008 from ongoing Phase 1b and 2 studies in multiple myeloma, lymphoma and solid tumors."

About Proteolix

Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancer and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in different types of cancer, Proteolix is developing next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this target class. Proteolix is headquartered in South San Francisco. For more information, please visit the Company's website at http://www.proteolix.com.

Contact: Stephen Brady, Executive Director of Business and Legal Affairs,

650-266-2621.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a ... conceive. , “If you are ready to have a baby, it’s best ... book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written for women ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... EVP and GM Jim Callandrillo and Duane Reed, VP of business development ... Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from May 15-17 ...
(Date:5/2/2016)... ... May 02, 2016 , ... For many artists, the act of ... has developed it into a science. , Using the new, highly precise METTLER ... shades that add depth and meaning to his works. What’s more, it has allowed ...
(Date:5/2/2016)... ... May 02, 2016 , ... Summit BHC (Summit), ... opening of Twin Lakes Recovery Center. Located east of Atlanta in Monroe, ... The residential facility is set on 34 acres of beautiful, secluded property ...
(Date:5/1/2016)... ... May 02, 2016 , ... ... original 1968 Jimi Hendrix Merriweather Post Pavilion in Columbia, Maryland concert posters. Dail ... poster. The concert was held on August 16. According to Hawley, “The Pavilion ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
Breaking Medicine Technology: